The history of cytoreduction and HIPEC: Heating up or just blowing smoke?

J Surg Oncol. 2024 Nov 3. doi: 10.1002/jso.27802. Online ahead of print.

Abstract

Peritoneal carcinomatosis carries a grim survival prognosis with complications ranging from the physical to the psychological. Cytoreductive surgery and infusion of heated intraperitoneal chemotherapy have evolved to become a commonly used treatment option in the multi-modal management of peritoneal carcinomatosis. Here, we examine the origins of surgery over a century ago as a potential cure for peritoneal carcinomatosis and how it has evolved with our knowledge of the disease to its present state. The origin of chemotherapy is similarly described as well as its progressive application in regional therapy, guided by the ongoing development of new agents, better understanding of peritoneal physiology, and improved systemic treatment. We show how these modalities began to be used in tandem, and standardized, leading to randomized trials and better understanding of the possibilities and limitations of treatment. Finally, we discuss the current status of patient selection for cytoreduction and future directions of intraperitoneal chemotherapy.

Keywords: HIPEC; carcinomatosis; cytoreduction; history; hyperthermic; intraperitoneal chemotherapy; peritoneal malignancy; peritoneal metastases; pseudomyxoma.

Publication types

  • Review